2 results
Approved WMORecruiting
Compare the clinical efficacy of Epcoritamab to SOC (R-GemOx or BR)
Approved WMORecruiting
Part 1: dose safety confirmationPrimary: To evaluate the proportion of participants with TRAEs leading to discontinuation within 12 weeks after the first dose of nivolumab plus2 different dose levels of relatlimab (360 mg and 720 mg) in combination…